Volta Medical is a pioneering health technology company developing artificial intelligence (AI) solutions to assist electrophysiologist physicians in treating complex cardiac arrhythmias such as atrial fibrillation (AF).
Volta’s overarching goal is to improve cardiac arrhythmia management by developing state-of-the-art, data-driven medical devices trained on large databases of procedural data with the highest standards of data protection.
Volta was founded in 2016 by Theophile Mohr-Durdez, Julien Seitz and Clément Bars. The company is headquartered in Marseille, France, with an office in Providence, Rhode Island.
Volta's cutting-edge software solutions use machine and deep learning algorithms to assist operators during cardiac ablation procedures. Volta’s DNA provides physicians with solutions that are user-friendly.
Volta's first product, VX1, is a digital AI companion device and algorithm to assist cardiologists with real-time identification of specific abnormal electrograms (EGMs), known as dispersed EGMs.
The VX1 real-time analysis algorithm has been trained on carefully curated databases of annotated intra-cardiac electrograms. The solution may be used as a support to assist electrogram-based atrial fibrillation ablation. VX1 was the first artificial intelligence-based software solution to be FDA cleared in the interventional cardiology space.
Volta is backed by Gilde Healthcare, Vensana Capital, Lightstone Ventures, Pasteur Mutualité, and others. The company raised €36M ($38M) in a Series B round on Jan 05, 2023. This brings Volta's total funding to $69.2M to date.